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Abstract
Background: Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate,
the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib,
up-to-date data on its effectiveness at the population level are limited.
Our study aims to assess the change in disease-specific survival for chronic myeloid leukemia after introducing
tyrosine kinase inhibitors in first-line treatment.
Methods: This study analyzed data from two population-based cancer registries in Italy. Disease-specific survival for
chronic myeloid leukemia cases diagnosed before and after the introduction of tyrosine kinase inhibitors (February
2002) were calculated up to 10 years. Hazard ratios were calculated using Cox regression models adjusted for sex,
age at diagnosis and residency. An interrupted time series analysis was also performed.
Results: Between 1996 and 2012, 357 new cases of chronic myeloid leukemia were diagnosed (standardized
incidence rate of 1.2 per 100,000 residents), quite constant throughout the period. The interrupted time series
analysis showed a gain of 40.4% in 5 years of disease-specific survival for chronic myeloid leukemia (from 47.3,
95%CI 38.5–55.5% to 80.8%, 95%CI 74.5–85.8%) after the introduction of tyrosine kinase inhibitors. The hazard ratio
was 0.36 (95%CI 0.25–0.52) for cases diagnosed after tyrosine kinase inhibitor introduction, with differences per age
at diagnosis: <65yo 0.17 (95%CI 0.08–0.39), >74yo 0.41 (95%CI 0.23–0.73). An improvement in survival (hazard ratio
0.66, 95%CI 0.36–1.20) was also observed in cases diagnosed before, and alive at, tyrosine kinase inhibitors
introduction.
Conclusions: Tyrosine kinase inhibitors increased disease-specific survival both for new and prevalent chronic
myeloid leukemia cases. The effectiveness was similar to that observed in trials only in patients ages 65 years or
younger.
Keywords: Chronic myeloid leukemia, Imatinib Mesylate, Survival analysis, Population registers, Interrupted time
series analysis
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Background
Chronic myeloid leukemia (CML) is a myeloproliferative
clonal disorder resulting from a neoplastic transform-
ation of hematopoietic stem cells [1]. CML affects
slightly more males than females and mainly between
the fifth and sixth decades of life [2]. In Italy, the crude
incidence rate is 1.61 per 100,000/year [3], and 5-year
relative survival is 74% [4]. In Europe, the incidence rate
is 1.10/100,000 [5].
Nowadays, the diagnosis of CML requires the detec-
tion of the BCR/ABL oncoprotein [6]. In cases diagnosed
before introducing the detection of BCR/ABL as diag-
nostic criterion, the protein was present in 95% of CML
patients [7]. The BCR/ABL oncoprotein is selectively
inhibited by imatinib mesylate [8], the first tyrosine kin-
ase inhibitor (TKI). Imatinib mesylate has transformed
CML from a fatal to a chronic disease. Thanks to the re-
sults of IRIS (International Randomized Study of Inter-
feron and STI571, [9]), imatinib was granted marketing
authorization within the European Union by EMA
(European Medicines Agency) in November 2001 [10]
and in the USA by the Food and Drug Administration in
May 2001.
According to the recommendation by the European
Society For Medical Oncology (ESMO) published in
2005, imatinib became the first-line standard treat-
ment for newly diagnosed patients with CML, with
cytogenetic and molecular response to be monitored
every six months [11].
However, tolerance and resistance to imatinib may de-
velop over time [12, 13]; the failure rate at 60 months for
patients receiving imatinib in the IRIS study was 17% [14].
In cases of failure of imatinib, second-line treatment
is based on second-generation TKIs such as dasatinib
and nilotinib [15, 16], authorized in November 2006
and November 2007, respectively [17, 18]. These new
drugs were initially approved for second-line treat-
ment through phase II studies [19], then, based on
the results of phase III studies, for first-line treatment
as an alternative to imatinib [20–22].
The IRIS trial showed a 5-year overall survival (OS) of
89% from the beginning of treatment [23]. A systematic
review of 29 clinical trials [24] confirmed these results:
an increase in 5-year survival, from 30 to 40% in the
pre-imatinib period (1980–87) to 96% after the introduc-
tion of the drug (2004–2005).
European and American population-based studies
showed that 5-year relative survival increased from 20 to
30% (1989–2001) in the pre-imatinib period to 50–90%
(2001–2013) in the post-imatinib period [25–31]. This
improvement occurred in all age groups, although older
patients had a worse survival rate.
Therefore, the extent of the overall improvement var-
ies among studies; some showed an increase in survival,
such as the RCTs, while others did not obtain very satisfac-
tory results. These differences can be explained by different
drug access among patients of different ages or from differ-
ent countries or by different characteristics among patients
enrolled in the trials and patients in observational studies,
who are a more heterogeneous group. Moreover, in a
“real-world” context, delayed treatment or non-adherence
to the TKI therapy is frequent and associated with critical
outcomes [32–34]. Up-to-date population-based data on
CML are limited [26].
The primary objective of our study is to assess the
change in disease-specific survival for CML after the
introduction of imatinib in first-line treatment.
The second objective is to assess potential demo-
graphic and geographic determinants of the change in
disease-specific survival for CML after the introduction
of imatinib.
Methods
Study design
This is a population-based study based on data from the
cancer registries of the Italian provinces of Modena and
Reggio Emilia.
Data sources
At-risk populations, used as a denominator for trend
analysis of incidence, were the resident populations in
the two provinces, as recorded by the population
registry of Emilia-Romagna Region on December 31
of each year considered (Source: Emilia Romagna
Population by age and sex, at http://statistica.regio-
ne.emilia-romagna.it/servizi-online/statistica-self-ser-
vice-1/popolazione/popolazione-per-eta-e-sesso).
Cancer cases were provided by the Modena and the
Reggio Emilia provinces’ cancer registries, which rou-
tinely collect data on incident cases of cancer among all
residents through the regional mortality, anatomical
pathology, laboratory and hospital discharge databases.
The Modena cancer registry was started in 1988, while
the Reggio Emilia registry was started in 1996. The two
cancer registries are validated according to national and
international standards by the Italian Network of Cancer
Registries (AIRTUM), the International Agency for Re-
search on Cancer (IARC) and the International Associ-
ation of Cancer Registries (IACR) and undergo annual
quality and completeness control processes.
Vital status during the follow-up period and the
causes of death were obtained through record linkage
with Local Health Authority and mortality registries.
Data on the introduction of first- and second-generation
TKIs (i.e. imatinib, dasatinib and nilotinib) in the two
provinces were collected using the regional hospital phar-
macy database, available since 2002.
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Furthermore, individual data on drugs, delivered by
hospital pharmacies to every patient, have been available
since 2007. As the data are anonymous, it was not pos-
sible to link drugs to CML cases, but only to quantify
the number of patients treated and to assess whether
second generation TKIs were used as first- or
second-line treatment. Moreover, as the use of TKIs was
approved in 2005 for a number of new indications, the
number of TKI users could be different from the num-
ber of CML cases.
Setting and population
Italy has universal health coverage provided by the Na-
tional Health Service through the Local Health Author-
ities in the 20 Regions. The provinces of Modena and
Reggio Emilia are in the Emilia-Romagna Region, in
northern Italy. The overall population in the two prov-
inces on December 31, 2012 was 1,242,286 residents;
21% of the overall resident population was over age
65 years.
Healthcare in these two provinces is provided by two
Local Health Authorities (with 11 hospitals), one univer-
sity hospital and one cancer research hospital. The pro-
vincial hematology units are located at the university
hospital in Modena (Azienda Ospedaliero-Universitaria
Policlinico di Modena) and at the cancer research hos-
pital in Reggio Emilia (Azienda USL-IRCCS of Reggio
Emilia).
Case definition
Our study included all cases of chronic myeloid
leukemia (ICD-10 code C92.1 or Morphology ICDO-3
codes 98,633, 98,753, 98,763) diagnosed from 1996 to
2012 and recorded in the Modena and the Reggio Emilia
cancer registries [35].
Exposure definition
The hospital pharmacies of the two hematology units
centers made their first purchase of imatinib in February
2002, three months after receiving marketing
authorization from the European Medicines Agency
(EMA).
Since 2002, imatinib has been authorized to treat
patients affected by CML resistant to interferon-based
therapy and not eligible for bone marrow transplant-
ation [36]. Due to its high efficacy in inducing
hematologic and cytogenetic remission and its better
tolerance compared to interferon, imatinib has been
recommended as first-line treatment since 2005 [11].
Despite this, according to the results from the IRIS
RCT published in 2003 [9], the use of TKI as
first-line treatment in real practice started prior to
2005, as reported for Sweden [37] and Italy.
For incident cases we considered those diagnosed after
February 1, 2002, the starting date of the imatinib
period. As a 6-month follow up was recommended for
CML patients, we adopted the date of August 1, 2002 as
the start date for changing therapy for prevalent cases
and thus exposed to imatinib.
Consequently, we classified the CML cases using the
date of diagnosis and vital status on August 1, 2002, ac-
cording to the following scheme:
 Pre-TKI cases referred to patients who were
diagnosed before February 1, 2002 and who died
before August 1, 2002, and were never exposed to
the new therapy;
 Prevalent cases referred to patients who were
diagnosed before February 1, 2002 and who were
still alive on August 1, 2002, for whom the exposure
was considered only for the period after August 1,
2002, using a time-dependent variable (see statistical
analysis section);
 Incident cases referred to patients who were
diagnosed after February 1, 2002 and who were
considered fully exposed to imatinib use.
As independent variables, we considered age at diagnosis,
gender and residency (mountainous or non-mountainous
area according to the Emilia-Romagna classification re-
ported in D.G.R. no. 1734/2004 and D.G.R. no. 1813/2009),
to assess whether potential geographic differences occurred
in accessing the new therapy.
Outcome and follow up
In the study period (i.e. 1996–2015), the overall mortal-
ity rate in Italy significantly decreased and the effect of
TKIs on overall survival may be overestimated due to
the reduction of other causes of death. Thus, we used
the disease-specific survival rate as the outcome, consid-
ering both CML and potentially CML-related causes of
death (i.e. other malignant or uncertain behavior,
hematological neoplasms, opportunistic infections and
anemia) (Additional file 1).
Vital status on December 31, 2015 was obtained
through record linkage with Local Health Authority and
mortality registries, which also led to the cause of death.
Statistical analysis
First, we performed a descriptive analysis of CLM cases
by sex, residency, age at diagnosis and exposure classifi-
cation (i.e. Incident, prevalent or pre-TKI). The
disease-specific survival rates at 1, 3, 5 and 10 years
(when possible) were also calculated. Kaplan-Meier sur-
vival curves for cases diagnosed before and after ima-
tinib introduction are also presented.
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Second, to assess whether the increase in survival was
due to early diagnosis, the incidence trend of CML was
calculated using the join-point regression analysis and
estimating the relative annual percentage change (APC)
[38]. In addition, a linear regression model was used to
evaluate whether there were any differences in age at
diagnosis during the study period.
Subsequently, the introduction and use of TKIs in
the provinces of Modena and Reggio Emilia was
assessed using hospital pharmacy databases in each
year of the study period. As individual data were
available only from 2007, TKIs users for the preceding
years were estimated applying a factor of 1/220 to
overall consumption (except for the first year), which
provides very similar estimates to actual users from
2007 onwards. The factor 1/220 was the actual num-
ber of doses prescribed per year per patient, as esti-
mated by the local hospital pharmaceutical services
(i.e. number of TKI users = number of TKI doses pre-
scribed in a year / n° of doses prescribed for each pa-
tient in one year). For the first year of drug
introduction (2002). the purchase of imatinib started
in February for incident cases and most likely in Au-
gust for prevalent cases. Therefore, a factor of 1/150,
calculated proportionally to the time of exposure
starting from the value of 220 per year, was used to
estimate TKI users.
For our primary objective, the impact of the introduc-
tion of the drug on disease-specific survival was evalu-
ated through interrupted time series (ITS) analysis. This
method makes it possible to detect whether a specific
intervention (TKI introduction) had significantly greater
effect than any underlying secular trend, interrupting the
previous trend and producing a level change in the out-
come, i.e. disease-specific survival [39]. A sensitivity ana-
lysis of ITS using the relative survival was also
performed.
A Cox model adjusted for sex, age at diagnosis and
residency was used to calculate the hazard ratio for inci-
dent cases compared to cases diagnosed before the
introduction of imatinib (i.e. prevalent and pre-TKI).
To evaluate the impact of the drug introduction on
prevalent cases, a Cox model with time-dependent vari-
able was used, including only cases diagnosed before
TKI introduction and surviving at least a year after diag-
nosis. In this model, the survival time of prevalent cases
was split into the period when they were considered not
exposed to TKI (from diagnosis to July 31, 2002) and the
period when they were considered exposed to TKI (from
August 1, 2002 onwards). The length of the split survival
times was limited to 5 years because there were no more
exposed survival times after 2002.
The Cox models for prevalent cases were also adjusted
for sex, age at diagnosis and residency.
The interactions between each independent variable
and exposure variable were also assessed to explore
whether the improvement in survival was different in
some categories. In any case, Cox models were stratified
by age class in order to evaluate whether age affected
the TKI impact.
Statistical analysis was performed using Stata software,
12.0 version. ITS analysis was performed using “ITSA:
Stata module” developed by Linden, Ariel [40].
Ethics
Data were treated according to the Italian Data Protec-
tion legislation (D.Lgs.n.196/2003). The Reggio Emilia
cancer registry received approval from the Provincial
Ethical Committee on July 23, 2014.
This is a retrospective observational study based on
cancer registry data. In accordance with the Italian priv-
acy law, no patient or parental consent is required for
large retrospective population-based studies approved by
the competent Ethics Committee if data are published
only in aggregated form.
Results
From 1996 to 2012, 357 new cases of chronic myeloid
leukemia were diagnosed in the provinces of Modena
and Reggio Emilia. The overall crude incidence rate was
1.7 for every 100,000 residents and the standardized in-
cidence rate was 1.2 for every 100,000 residents. In the
same period, the trend in incidence rates was substan-
tially constant (APC -2.3, 95%CI -5.1-0.6) (Fig. 1) while
the mean age at diagnosis was higher for cases diag-
nosed before drug introduction (63.4 years, 95%CI 60.3–
66.5) compared to those diagnosed after February 1,
2002 (59.5 years, 95%CI 57.0–61.9)(coef = − 3.9, p =
0.048).
TKI volume
Figure 2 shows the volume of TKIs administered
since 2002, year of introduction of imatinib as a
first-line treatment for CML, extracted from the hos-
pital pharmacy databases of the provinces of Modena
and Reggio Emilia. The use of second-generation
TKIs started in 2007 for dasatinib and in 2009 for
nilotinib (Fig. 2).
Moreover, the analysis of individual hospital pharmacy
utilization from 2007 to 2016 showed that
second-generation TKIs was prescribed as a second-line
treatment in 98.3% (N = 116/118) of cases, in accordance
with the current guidelines. The estimated number of TKI
users has at least equaled the number of prevalent cases
only since 2004, with a gap in 2002 and 2003.
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CML cases description and survival analysis
The characteristics of the cases are summarized in
Table 1 according to the exposure variable: 75 cases
were classified as pre-TKI, 73 as prevalent and 209 as
incident.
The disease-specific survival rate for CML was higher
for incident cases than for cases diagnosed before Febru-
ary 1, 2002, both at 3, 5 and 10 years (Table 1).
Kaplan–Meier analysis showed a difference in survival
rate between cases diagnosed before and after imatinib
introduction, starting from the first year and with a con-
stant difference of almost 35% by the 10th year (Fig. 3).
The ITS analysis showed a positive level change fol-
lowing the drug introduction of 35.9% (p = 0.000) on
3-year disease-specific survival (Fig. 4a), which is equal
to 40.4% (p = 0.000) on 5-year disease-specific survival
Fig. 1 Trend in incidence rates of chronic myeloid leukemia from 1996 to 2012 in the provinces of Modena and Reggio Emilia, Italy
Fig. 2 Number of prevalent cases of CML, number of TKI users (numbers on graphic area) and number of posological units (pills) of imatinib,
dasatinib and nilotinib delivered per year by the hospital pharmacy to inpatients resident in the provinces of Modena and Reggio Emilia. Data
from hospital pharmacy databases
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(Fig. 4b). After 2002, no change in trends was observed
(p = 0.66 for 3 years; p = 0.53 for 5 years). The results
were consistent with those of the sensitivity analysis
using relative survival (data not shown).
The hazard ratios (HR), adjusted for sex, age at diag-
nosis and residency, showed a significant effect of the
drug introduction on incident cases (HR = 0.36, 95%CI
0.25–0.52) compared to other cases.
Moreover, survival was higher for female and younger
patients, while no differences were detected for resi-
dency (Table 2).
No interaction was found between the incidence
period and sex, residency and age (test for interaction p
= 0.655, 0.314, 0.161, respectively). Stratifying the model
by age class at diagnosis, the effect of TKI introduction
on survival was stronger in younger patients (HR = 0.17
95%CI 0.08–0.39).
Cox model performed to assess the impact of TKI
introduction on prevalent CML cases, i.e. those diag-
nosed before February 1, 2002, showed a slightly positive
effect on the risk of dying of CML in the survival period
post-TKI compared to the pre-TKI period. Again, we did
Table 1 Chronic myeloid leukemia case description and survival analysis
CML Case Characteristics DIAGNOSIS PRE-TKI
(before February 1, 2002)
DIAGNOSIS Post-TKI
(after February 1, 2002)
dead on August 1, 2002
(Pre-TKI cases)
alive on August 1, 2002
(Prevalent cases)
(Incident cases)
SEX N % N % N %
M 48 64.0 42 57.5 117 56.0
F 27 36.0 31 42.4 92 44.0
AGE AT DIAGNOSIS
< 65 yrs 17 22.7 40 54.8 117 56.0
65–74 yrs 23 30.7 22 30.1 46 22.0
> 74 yrs 35 46.7 11 15.1 46 22.0
RESIDENCY
non-mountainous area 64 85.3 65 89.0 193 92.3
mountainous area 11 14.7 8 11.0 16 7.7
TOTAL 75 100 73 100 209 100
SURVIVAL Diagnosis before February 1, 2002 Diagnosis after February 1, 2002
Relative Survival
% (95% CI)
Disease-specific Survival
% (95% CI)
Relative Survival
% (95% CI)
Disease-specific Survival
% (95% CI)
1 year 81.43%
(73.55–87.47)
83.36%
(76.21–88.53)
90.54%
(85.31–94.22)
91.28%
(86.52–94.42)
3 years 56.55%
(47.34–65.06)
60.38%
(51.69–68.00)
80.95%
(74.26–86.40)
84.52%
(78.70–88.86)
5 years 40.82%
(31.96–49.75)
47.26%
(38.49–55.53)
77.01%
(69.65–83.25)
80.85%
(74.49–85.78)
10 years 34.50%
(25.76–43.76)
38.41%
(29.90–46.85)
70.85%
(61.55–79.08)
76.97%
(69.52–82.82)
5-yr SURVIVAL by AGE AT DIAGNOSIS Diagnosis before February 1, 2002 Diagnosis after February 1, 2002
Relative Survival
% (95% CI)
Disease-specific Survival
% (95% CI)
Relative Survival
% (95% CI)
Disease-specific Survival
% (95% CI)
< 65 yrs 66.34%
(51.84–77.60)
69.08%
(55.03–79.52)
92.49%
(85.31–96.59)
94.63%
(88.41–97.55)
65–74 yrs 39.31%
(23.83–55.31)
46.77%
(30.83–61.22)
67.59%
(50.58–81.06)
69.01%
(52.50–80.78)
> 74 yrs 3.49%
(0.28–15.97)
8.05%
(0.81–26.72)
40.27%
(22.01–60.78)
51.21%
(32.44–67.17)
Characteristics of cases of chronic myeloid leukemia diagnosed from 1996 to 2012 in the provinces of Modena and Reggio Emilia, Italy, classified by date of
diagnosis (before or after February 1, 2002) and status (dead or alive) on August 1, 2002. February 1, 2002 was the date of the first purchase of imatinib by the
Local Health Authorities of Modena and Reggio Emilia and August 1, 2002 was the date of the plausible full implementation of the new therapy for all the
prevalent cases, according to current guidelines. Disease-specific survival was assessed for all cases with follow up to December 31, 2015. Five-year disease-
specific survival stratified by age class at diagnosis was also calculated
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not find any interaction with sex and residency (test for
interaction p = 0.731 and 0.122, respectively), while there
seemed to be one with age (test for interaction p =
0.053), with a stronger effect for younger patients
(Table 3).
Discussion
In our study, disease-specific survival for CML increased
sharply after the introduction of imatinib (February 1,
2002), by 35.9% at 3 years and 40.4% at 5 years, reaching
80.9% in the post-TKI period.
The diffusion of TKI administration was quite rapid,
plateauing in 2009. The estimated number of TKI users
was lower than the number of prevalent cases of CML
for the first two years after imatinib introduction. More-
over, since 2005, the number of TKI users was higher
than prevalent cases due to the increasing number of in-
dications of these drugs (i.e. malignant gastrointestinal
stromal tumors, dermatofibrosarcoma protuberans,
acute lymphoblastic leukemia, chronic eosinophilic
leukemia, hypereosinophilic syndrome, myelodysplastic/
myeloproliferative diseases) [41–45].
The impact of TKI use on disease-specific survival was
greater on patients diagnosed after drug introduction
(after February 1, 2002) but a positive effect was also
seen on prevalent cases. An effect of shifting the therapy
in prevalent cases has not been described before. In this
population, the interaction with age is stronger with
older patients diagnosed before 2002, who barely
benefitted from the introduction of TKIs, probably be-
cause they never received the new treatment.
No differences were found in relation to the residency
of patients, suggesting a uniform access to the new
drugs in all areas, even mountainous ones, which are far-
ther from the hematological units.
Considering age at diagnosis, our results were partially
consistent with those from previous studies [25, 26],
which highlighted a greater benefit for younger patients.
The increase in survival was minimal in countries where
TKI-treatment was not as widespread.
In a Lithuanian study, the 5-year relative survival (RS)
ranged from 33% in 2000–2004 to 55% in 2005–2009,
but throughout the entire study period the 5-year RS of
33% was limited to patients ages 65–74, while for those
ages ≥75 it was only 18%. TKI availability (imatinib in
first-line treatment) increased from 1.5% in 2000–2004
to 30.6% in 2005–2009 and was restricted to younger
groups. In the same study from Lithuania, during 2000–
2004, only the < 44-year age group was treated with ima-
tinib (7% of penetrance) while in 2005–2009, the TKI
penetrance of patients < 65 years was 49.5%, and until
2009, no one over age 75 received the new drug [31].
Instead, the improvement in survival was highest in
previous studies from countries where first-line
TKI-treatment was available to almost everyone patients.
In a previous population-based Swedish study, the
5-year RS ranged from 21% (1973–79) to 80% (2001–
2008) but this improvement was greater in younger
Fig. 3 Kaplan-Meier disease-specific survival curves for chronic myeloid leukemia: Kaplan-Meier disease-specific survival curves of chronic myeloid
leukemia cases diagnosed before (pre-TKI) and after (post-TKI) the introduction of imatinib on February 1, 2002
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patients: in the period 2001–2008, the < 50 years group
showed a 5-year RS of 91% while the > 79 age group
showed a 5-year RS of 25%. The use of imatinib in
first-line treatment increased from 40% in 2002 to 84%
in 2006 [25].
The results from another study suggest that the
smaller gain in survival for older patients was not due to
age-related characteristics. In fact, in the UK, the 5-year
RS was 88.6% in the period between 2004 and 2013
(89.9% for patients < 60 years and 87.2% for ≥60 years)
and 97% of patients received imatinib or dasatinib in
first-line treatment [26]. In our study, the overall 5-year
disease-specific survival was lower (80.8%), while the re-
sults were similar for younger patients (94.6% for those
age < 65), with a higher gap for older patients (69.0% in
patients age 65–74 and 51.2% in those age > 74). This
Fig. 4 Interrupted time series analysis: The level change in 3-year (a) and 5-year (b) disease-specific (DS) survival for CML after the introduction of
TKI (intervention) was calculated using interrupted time series regression models. Points represent disease-specific survival by year of diagnosis,
continuous lines represent pre- and post-intervention trends, the dashed line represents the time of intervention, i.e. the drug’s introduction into
clinical practice in February 2002
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difference could be due to a slower penetration of the
new therapy in the first years after introduction, particu-
larly among older patients.
Moreover, 5-year leukemia-related survival of 93% was
observed in a population-based prospective Italian study
of CML patients (> 18 years old) living in two Italian re-
gions, diagnosed during 2008–2012 and 2010–2012, re-
spectively [46]. In this study, 5-year disease-specific
survival ranged from 94% among patients age 18–
69 years to 88% for patients age 80 or older. The lower
survival rate achieved by older patients in our study
might be due to the different causes of death considered
for estimating disease-specific survival (i.e. only deaths
after documented progression to accelerated or blastic
phases were considered by Castagnetti et al.). Moreover,
as the Italian study period began long after the introduc-
tion of imatinib, its results were probably less affected
by the slower introduction of the drug compared to our
study. Future research should explore whether differ-
ences in TKI prescription in the elderly population are
the cause of the lowered impact on relative survival. Fi-
nally, Castagnetti et al. reported only the results con-
cerning cases actually treated with imatinib, as with
documented Ph + CML. Due to the unavailability of the
specific morphology of the older cases included in our
registry, CML Ph- was also included, with a plausible re-
duction in the impact of the drug introduction.
Strengths and limitations
As in any observational study with a before and after de-
sign, other factors may have changed during our study
period, making the two populations (pre- and post-TKI
introduction), not comparable. To support a causal link
between the observed change in survival and the intro-
duction of TKI we should rule out that other changes
occurred in the epidemiology of the disease in the same
time period. Early diagnosis has the potential to strongly
impact survival, so we should rule out that cancers in
the post-introduction period were diagnosed earlier than
those in the pre-introduction period. Indeed, we ob-
served a slight decrease in mean age at diagnosis during
the study period. This change could be due to early diag-
nosis in the post-TKI introduction period or delay in
registration in the first years of the follow-up period (i.e.
the inclusion of prevalent cases, diagnosed before the
start of the registry activity, in the incidence of the first
years of registration, corresponding to the pre-imatinib
period in our study). Nevertheless, this difference in age
at diagnosis cannot explain the enormous increase in
survival rate that we observed. In fact, the mean age at
diagnosis decreased by 3.9 years but the distance be-
tween the two curves is much higher after the second
year. Furthermore, the difference in survival curves is
mostly due to a difference in the fraction of remaining
patients when the curves became approximatively flat: in
the post-imatinib introduction period, about 75% of pa-
tients were still alive compared to 35% in the
pre-imatinib period.
The design of our study reflected the real impact on
the entire population of CML patients, not considering
whether they were correctly diagnosed and characterized
or whether they actually received imatinib. We are
measuring both the efficacy of the treatment, which is
assumed in this study, and the ability of the health ser-
vice to correctly treat patients with a newly available and
very effective drug.
Moreover, the available routinely collected data did
not make it possible to assess the real individual uptake
of TKIs. Despite this, data on the delivery of TKIs in our
province and the current guidelines support an almost
full implementation of TKI in CML cases in the study
period.
In addition, the impact of second-generation TKIs was
not assessed separately, although data from hospital
pharmacy databases suggest that they were only used in
second-line treatment during the study period, therefore
less than imatinib.
Finally, data on cytogenetics of CML were not avail-
able for the older cases included in our registry and the
Table 2 Hazard ratios (HR) for incident cases
HR [95% CI]
Cox model for incident cases
Period of diagnosis
Post-TKI vs. Pre-TKI 0.36 0.25 0.52
Sex
F vs. M 0.65 0.45 0.93
Age at diagnosis
65–74 yrs vs. < 65 yrs 3.46 2.19 5.47
> 74 yrs vs. < 65 yrs 8.27 5.16 13.26
Residency
Mountainous vs. non-mountainous 1.13 0.67 1.92
Cox model for incident cases stratified by age at diagnosis
Age at diagnosis < 65 years
incident cases vs. non-incident cases 0.17 0.08 0.39
Age at diagnosis 65–74 years
incident cases vs. non-incident cases 0.52 0.27 0.99
Age at diagnosis > 74 years
incident cases vs. non-incident cases 0.41 0.23 0.73
Hazard ratios for incident cases (diagnosed after February 1, 2002) compared
to other cases (diagnosed before February 1, 2002), calculated using Cox
regression models adjusted by sex, age at diagnosis and residency
(mountainous or non-mountainous area). Interaction between each covariate
and time of diagnosis (i.e. incident or non-incident cases) was also assessed. A
Cox regression model stratified by age at diagnosis and adjusted for sex and
residency for incident cases was also performed
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exclusion of the more recent CML Ph- cases might
introduce a bias in the trend analysis. Therefore, we in-
cluded all the CML cases in our analysis, with a poten-
tial reduction of estimated imatinib impact on survival
rate. Despite this, using data from cancer registries and
mortality registries allowed us to include almost all CML
cases among residents in the two provinces.
Conclusions
The spread of TKI use in Emilia-Romagna was quite
rapid and caused an immediate increase in CML sur-
vival, both for new cases and prevalent ones. The impact
on survival was similar in all geographic areas and in
both sexes, but patients over the age of 65 years ob-
tained a smaller gain. The 5-year disease-specific sur-
vival in patients < 65 years diagnosed in the post-TKI
period reached values similar to those observed in RCTs.
The effectiveness of TKIs proved to be similar to efficacy
only in younger patients.
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